CBSC activates China manufacturing pipeline and advances MyCardia AT into final NMPA submission phase with Ebulent Medical.

心脏生物科技解决方案激活MyCardia AT中国生产流程并进入NMPA最终申报阶段

CBSC activates China manufacturing pipeline and enters final NMPA submission phase for MyCardia AT cardiac monitoring device.

正式发布新一代MyCardia AT心脏监测仪

CB Scientific, Inc. (CBSC) has officially launched its next-generation MyCardia AT cardiac event monitor in collaboration with Datrix, LLC. Designed for enhanced remote cardiac monitoring, the FDA-cleared device offers a lightweight, easy-to-use design with seamless integration into the MyCardia app ecosystem. The MyCardia AT monitor enables early detection of cardiac arrhythmias, helping physicians diagnose transient heart conditions more effectively. The device is set to roll out across SE Asia, Hong Kong, Macau, and pending regulatory approvals, Canada and China.

CB科学公司完成年度股东大会

Shareholders endorse name change to Cardiac Biotech Solutions, Inc. subject to regulatory approval

How can we help you?

Tell us what you are interested in.

订阅我们的新闻邮件!

订阅我们的电子报,我们将直接向您发送最新消息。